Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib for refractory/recurrent pediatric Langerhans cell histiocytosis
ChiCTR2100045125Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trametinib in Langerhans cell histiocytosis (LCH), sponsored by Beijing Children's Hospital. Primary endpoints: objective response rate at 12 months, disease control rate at 12 months and 2 more. Started Apr 2021; status: recruiting.
02
Drugs
trametinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2100045125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045125.